Categories Uncategorized

Peyote: The Less-Known Psychedelic with Numerous Benefits

Psychedelics such as LSD, MDMA, ayahuasca and psilocybin have become popular in the last few years as researchers discover more about the substances and the therapeutic benefits they possess. While these substances have been a part of the popular culture in the West for some decades now, other psychedelics, including peyote, have been used by Indigenous people in spiritual and healing practices for many millennia.

Peyote, which is a less-popular psychedelic, is a spineless cactus that naturally grows in various parts of Mexico and Southern Texas. The cactus is small and bears the shape of a caterpillar cocoon, which explains how it got its name.

The peyote cactus contains different psychoactive compounds, with one of them — mescaline — being responsible for most of the psychedelic effects the cactus induces. The cactus is considered to be sacred to Indigenous populations in the region.

A report released more than a decade ago utilized radiocarbon dating to determine the age of two peyote samples that were discovered in Native American ruins. The findings noted that the samples dated back more than 5,000 years, which suggests that Native Americans have used peyote’s psychoactive effects for thousands of years now.

Similar to other psychedelics, mescaline activates the brain’s serotonin 2A receptors when ingested. This indicates that experiences under the influence of peyote may be similar in some ways to experiences on psilocybin and LSD.

Like other psychedelic substances, peyote’s effects will depend on an individual’s surroundings while under the influence, their mindset and the amount an individual has consumed. When individuals consume small doses of the psychoactive compound, they may feel more energized or experience some perceptual distortions. However, consuming larger doses may have greater effects on an individual’s state of consciousness and their perception as well as their cognition. The possible effects of peyote when consumed in heavier doses include anxiety, nausea, strong hallucinations and mystical-type experiences. The psychedelic’s effects typically last about 10 hours.

The substances also possess various health benefits. A study published this year found that using mescaline was linked to a decrease in symptoms of PTSD, anxiety and depression. The study also found that participants who had a history of substance and alcohol use disorders recorded a considerable decrease in drug and alcohol use after mescaline experiences.

Apart from its use in religious ceremonies by the Native American Church, peyote has also been used as a treatment for drug addictions, alcoholism, childbirth pain and toothache by Native Americans, who claim that it has healing properties.

As more becomes known about the different therapeutic uses of psychedelics, the work of companies such as Cybin Corp. (NEO: CYBN) (OTCQB: CLXPF) will be appreciated for its trail-blazing role in taking psychedelics to the mainstream of medicine.

NOTE TO INVESTORS: The latest news and updates relating to Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) are available in the company’s newsroom at https://ibn.fm/CYBN

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.psychedelicnewswire.com

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Chris@PNW

Share
Published by
Chris@PNW

Recent Posts

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary to Acquire 49% Stake in Prominent Florida Neuropsychiatry Clinic

The acquisition of Cohen and Associates, a respected interventional psychiatry practice, by NRx subsidiary HOPE…

1 week ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Applies for FDA Commissioner’s National Priority Voucher for IV Ketamine NRX-100

The new FDA voucher program aims to speed approval of drugs aligned with national health…

3 weeks ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Files Abbreviated New Drug Application for Preservative-Free IV Ketamine NRX-100 Amid Ongoing Shortage

The company targets all current ketamine indications, including anesthesia and pain management. The U.S. is…

1 month ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a…

1 month ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Announces $10.3 Million Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval

Subsidiary HOPE Therapeutics signed a $7.8 million debt financing term sheet with Universal Capital. Combined…

2 months ago

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition

Kadima Neuropsychiatry Institute is expected to become the clinical model for HOPE Therapeutics’ nationwide network…

2 months ago